#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Familial haemophagocytic lymphohistiocytosis Mantle cell lymphoma stage II T-cell type acute leukaemia Leiomyosarcoma metastatic Hodgkin's disease refractory Raynaud's phenomenon Granulomatosis with polyangiitis Ocular lymphoma Inflammatory myofibroblastic tumour Acute hepatic failure Arterial disorder Hyperadrenocorticism Desmoid tumour Loss of consciousness Iron overload More trials…

    Learn about Rare Diseases

    VEXAS syndrome – Treatment Soft tissue sarcoma – Treatment Medulloblastoma – Trials in Disease Richter’s syndrome Amyotrophic lateral sclerosis – Basic Information Anaplastic thyroid cancer – Basic Information X-linked lymphoproliferative syndrome – Diagnostics Hereditary ataxia – Trials in Disease KBG syndrome – Life with Disease Glycogen storage disease type I More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Indacaterol MAGNESIUM ACETATE TETRAHYDRATE GS-4321 Ertapenem Sodium Prednisone Acetate Ambrisentan Hyoscine Butylbromide Glipizide Tuvusertib Tirbanibulin Ivabradine Absk021 Hydrochloride Hydrate Ddcart‐Cd19 Cefoxitin Sodium Vericiguat Gozetotide Alf-18 Ponatinib [68GA]GA-NOTA-AE105 Nepafenac Fluocinolone Acetonide More therapies…

    Learn about Your Condition

    Cardiac disorder Non-small cell lung cancer Glomerulonephritis membranous Erdheim-Chester disease CADASIL Autoimmune hepatitis T-cell lymphoma Partial lipodystrophy Enteritis Astrocytoma malignant Double hit lymphoma Myocardial infarction Triple negative breast cancer Short-bowel syndrome Post procedural infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study on Mavorixafor for Patients with Chronic Neutropenia Experiencing Recurrent or Serious Infections

    Recruiting

    3 1
    Investigated Drugs:
    • Mavorixafor
    Belgium Czechia France Germany Greece Hungary +6

  • Study on the Effects of Donepezil in Patients with Anorexia Nervosa

    Recruiting

    2 1 1
    Investigated Diseases:
    • Anorexia nervosa
    Investigated Drugs:
    • Donepezil Hydrochloride
    France

  • Study on the Effects of Methylprednisolone in Infants with Neuroendocrine Cell Hyperplasia

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Methylprednisolone Hydrogen Succinate
    • Methylprednisolone
    • Lidocaine Hydrochloride Monohydrate
    France

  • Study on Adding Sulfasalazine, Idarubicin, and Cytarabine to Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia in Patients Aged 60 and Older

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Sulfasalazine
    • Idarubicin Hydrochloride
    • Cytarabine
    France

  • Study of RMC-6291 and Pembrolizumab with or without Chemotherapy for Patients with Advanced KRAS G12C Mutated Lung Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Rmc-6291
    • Cisplatin
    France Germany Italy The Netherlands Spain

  • Study of Valproic Acid, Capecitabine, and Radiotherapy for Patients with Low-Moderate Risk Rectal Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Valproate Semisodium
    • Capecitabine
    Italy
Previous Page
1 … 503 504 505 506 507 … 1,653
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!